How I Treat Patients with Progressive Myelofibrosis
Myelofibrosis, whether primarily originating from a central thrombocythemia or polycythemia vera, is by nature a progressive myeloid neoplasm with worsening cytopenias, splenomegaly symptoms, and potential progression to acute myeloid leukemia. The approval of ruxolitinib has been a tremendous benefit of two patients with myelofibrosis having extended survival and improved splenomegaly and symptoms; however, unmet needs exist. Dr. Mesa will take a case-based approach to different progressive scenarios these patients can face and how to overcome them with current investigational therapies, off study regimens, off study pharmacologic regimens, non-pharmacologic interventions, and allogenic stem cell transplantation. The most recent information regarding investigational agents will be woven into a discussion that balances against other options these patients have that clinicians may well be able to utilize.
Ruben A. Mesa
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members